0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-374.68%PremiumNov 15, 2024Expiry Date5.92Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.26Leverage Ratio--Theta--Rho--Eff Leverage--Vega
LAVA Therapeutics Stock Discussion
LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology. $LAVA Therapeutics (LVTX.US)$
https://stockregion.app/p/biotech-leader-announces-7m-milestone
No comment yet